Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Valid measure of antidepressant efficacy in primary care is needed
| The first 150 words of the full text of this article appear below. |
EDITOR
The study by Philipp et al comparing hypericum extract and
imipramine or placebo seems to show that hypericum is as effective at
treating moderate depression as imipramine.1 This impression is strengthened by the design of the study, which is double
blind, randomised, and placebo controlled, using a widely used
medication as a comparator and using globally accepted depression scales including the Hamilton depression score. Linde and Berner, however, in the accompanying commentary question the efficacy of
hypericum because of its use in comparatively large doses and its
comparison with low doses of standard antidepressants.1 They believe that these, together with the effect of unblinding on
outcome, should be taken into account in the analysis of the results.
The basis of this criticism is the lack of universal consensus on how
the effects of antidepressant drugs should be measured in primary care.
Difficulty arises because lower doses are often
Read all Rapid Responses